Study Finds Azacitidine Kills Leukemia Cells Via RNA, Not DNA

Researchers and clinicians have classified azacitidine as a DNA hypomethylating agent for more than two decades, using it to treat high-risk myelodysplastic syndromes and acute myeloid leukemia.

A study published in Molecular Cell reveals that during the first day of treatment—when the drug kills the greatest number of cancer cells—almost none of that activity occurs in DNA. It happens primarily in RNA.

Changes in gene activity frequently failed to match changes in DNA methylation, leaving clinical puzzles unresolved. Some patients benefited from treatment even without measurable DNA demethylation.

Researchers at the University of Chicago and UT Health San Antonio compared azacitidine with decitabine, a sister drug engineered so that only DNA will take it up. Decitabine acts solely through DNA.

If DNA were the substrate, then decitabine should work better than azacitidine, but it is the opposite.

Chuan He, University of Chicago

“Both are used as hypomethylating agents to treat leukemia, but azacitidine is used in the majority of patients and decitabine in a smaller portion,” said He, the study’s senior author and the John T. Wilson Distinguished Service Professor of Chemistry at the University of Chicago, as reported by UChicago.

Co-authors include Boyang Gao, affiliated with the University of Chicago and the Max Planck Institute of Immunobiology and Epigenetics in Germany. Xinyuan Ma, Long Zhao, Zhongyu Zou, Junhong Xiang, and Xiaoyang Dou represent the University of Chicago. Ying Li, Juyeong Hong, Feng-Chun Yang, and Mingjiang Xu represent the University of Texas Health Science Center at San Antonio, Texas.

Passive DNA demethylation requires cell division while RNA effects occur much faster. The team focused on the initial 8 to 24 hours of treatment.

The team measured chemical tags over time using high-precision mass spectrometry. Levels of a tag known as 5-methylcytosine on chromatin-associated RNA dropped sharply within 8 hours, while DNA methylation remained completely unchanged throughout the first 24 hours.

The drug bound directly to NSUN2, the primary enzyme responsible for installing those methyl tags on chromatin-associated RNA, according to biochemical isolation techniques. That binding peaked at 8 hours, matching the moment RNA methylation dropped and gene activity shut down.

Investigators used genetic tools to deplete NSUN2 without administering the drug. The leukemia cells collapsed in the identical manner observed under azacitidine treatment, halting division and losing DNA repair capabilities.

Azacitidine triggers cell death within hours. That rapid action explains its strong synergy with venetoclax, a drug that prompts cancer cells to self-destruct, making the combination a standard treatment for many older adults suffering from acute myeloid leukemia.

Leukemia cells carrying mutations in TET2 or IKZF1 genes showed increased sensitivity to the loss of RNA methylation. This offers potential biomarkers doctors can use to predict patient response.

Chuan He, a Chinese-American chemical biologist, is best known for discovering and deciphering reversible RNA methylation in post-transcriptional gene expression regulation. He proposed in 2010 that RNA modifications could be reversible and regulatory, then discovered the first RNA demethylase that oxidatively reverses N6-methyladenosine methylation in mammalian mRNA in 2011.

His work elucidated the functional roles of mRNA methylation and identified direct reader proteins for m6A. He was awarded the 2023 Wolf Prize in Chemistry for these contributions and is an Investigator of the Howard Hughes Medical Institute.

Funding for the research—entitled “5-Azacytosine induces cytotoxicity via 5-methylcytosine depletion on chromatin-associated RNA in leukemia,”—came from the National Institutes of Health, the Ludwig Center for Metastasis at the University of Chicago, and the Cancer Prevention and Research Institute of Texas.

Photo of author

Health Desk

Health Desk at Archyde.

Researchers Detail Automated Dish System for Assisted Reproductive Technology